desipramine and mirabegron

desipramine has been researched along with mirabegron in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dickinson, J; Krauwinkel, W; Meijer, J; Schaddelee, M; Strabach, G; Tretter, R; van de Wetering, J; van Gelderen, M	1
Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K	1

Trials

1 trial(s) available for desipramine and mirabegron

Article	Year
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult	2014

Article

Year

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.

European journal of drug metabolism and pharmacokinetics, 2014, Volume: 39, Issue:1

Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Thiazoles; Urinary Bladder, Overactive; Young Adult

2014

Other Studies

1 other study(ies) available for desipramine and mirabegron

Article	Year
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Biopharmaceutics & drug disposition, 2019, Volume: 40, Issue:5-6 Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholinesterase; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Desipramine; Drug Interactions; Female; Gemfibrozil; Glucuronosyltransferase; Humans; Itraconazole; Lorazepam; Male; Middle Aged; Models, Biological; Renal Insufficiency; Thiazoles; Young Adult; Zidovudine	2019

Article

Year

Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.

Biopharmaceutics & drug disposition, 2019, Volume: 40, Issue:5-6

Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholinesterase; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Desipramine; Drug Interactions; Female; Gemfibrozil; Glucuronosyltransferase; Humans; Itraconazole; Lorazepam; Male; Middle Aged; Models, Biological; Renal Insufficiency; Thiazoles; Young Adult; Zidovudine

2019